2010

  • CadiAQ Valve Technologies presents at TCT 2010

    September 20, 2010

    CardiAQ Valve Technologies (“CVT”) to present latest in vivo results of its TranscatheterMitral Valve Implantation (TMVI) System on Wed., Sept. 22, at “TCT 2010” Repeatedly successful in vivo deployments of a mitral tissue valve implant via a transcatheter approach further validate CVT’s non-surgical solution to mitral regurgitation (MR) IRVINE, Calif., Sept. 20, 2010: Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), anno

    Read More
  • miRagen Therapeutics, Inc. forms alliance with Santaris Pharma

    June 23, 2010

    Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-targeted Medicines for the Treatment of Cardiovascular Disease • miRagen licenses rights to utilize Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against miRagen’s proprietary microRNA targets for the treatment of cardiovascular disease • Santaris Pharma A/S obtains a minority equity interest in miRagen in addition to milestone payments and royalties on LNA-based medicines developed as part of the collaboration • miRagen, a l

    Read More
  • CardiAQ Valve Technologies moves to new headquarters in Irvine, CA

    June 1, 2010

    CardiAQ Valve Technologies (“CVT”) completes move of its headquarters to a specialized facility in Irvine, Calif., and announces expansion of its product development team IRVINE, Calif., June 1, 2010—Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that it has established operations in Irvine, Calif. The 8,500-square-foot operation is a state-of-the-art research, development and manufacturing facility—with mi

    Read More
  • CardiAQ Valve Technologies presents at EuroPCR 2010

    May 20, 2010

    CardiAQ Valve Technologies (“CVT”) to disclose data during “EuroPCR 2010” about the world’s first successful in vivo transcatheter delivery of a mitral heart valve implant Successful deployment of a mitral tissue valve implant via a transcatheter approach validates CVT’s non-surgical solution to mitral regurgitation (“MR”) IRVINE, Calif., May 20, 2010—Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced toda

    Read More
  • CardiAQ Valve Technologies closes $6.5M Series A

    January 12, 2010

    Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that it has closed a $6.5 million ‘Series A’ funding led by a group of private investors with proven expertise in the transcatheter heart valve space. The funding, which incorporates conversion of all previous debt, will be used to technically and clinically validate the CVT technology and is expected to carry the Company through initial first-in-man studies. “This fun

    Read More